Immunotherapy for high-risk T-cell blood cancers after transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 study tests a targeted immune treatment given after strong pre-treatment (myeloablative chemo plus total-body radiation) before or along with an allogeneic stem cell transplant. It may help prevent the cancer from coming back in young people with high-risk T-cell ALL or certain T-cell lymphomas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 0 to 39 years.
- You have T-cell ALL in your second or later remission, or T-cell lymphoma that is in complete response after re-induction treatment.
- A stem cell transplant from a donor must be planned and the donor must be found.
- You need to be well enough to participate (performance status at least 60%) and have recovered from side effects of past treatments.
- You must meet standard blood, liver, kidney, and other organ function requirements.
- You (or your guardian) must be able to sign the study consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests daratumumab (a targeted antibody medicine) in people with T-cell ALL whose leukemia is not fully gone at very low levels. The goal is to eliminate “minimal residual disease” (MRD) that can predict relapse, so treatment may be more effective after intensive chemotherapy.
This trial tests a new treatment using specially engineered immune cells (CAR T cells) from a past stem cell donor to attack cancer cells in people with certain types of T-cell cancers that have returned after a stem cell transplant. The goal is to see if this treatment can lead to remission so a second stem cell transplant can be done.
This trial tests if adding the drug daratumumab can clear remaining cancer cells in people with T-cell acute lymphoblastic leukemia (T-ALL) who still have a small amount of leukemia after initial chemotherapy. It aims to reduce the risk of the cancer coming back.
This trial tests whether adding the drug daratumumab to usual chemotherapy helps children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL). The goal is to see if the combination improves outcomes without increasing side effects.
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
This trial tests a new combination of a targeted drug (daratumumab) plus chemotherapy, followed by a stem cell transplant, for people with a rare and aggressive blood cancer called primary plasma cell leukemia. The goal is to see if adding daratumumab improves the chances of getting rid of the cancer and staying in remission.
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.